CRO Analytics, ACRP Partner To Assess Clinical Trial Quality
CRO Analytics, a provider of validated clinical trial performance data, announced a partnership with the Association of Clinical Research Professionals focused on measuring investigator site personnel views of clinical trial quality
CRO Analytics, a provider of validated clinical trial performance data, announced a partnership with the Association of Clinical Research Professionals (ACRP) focused on measuring investigator site personnel views of clinical trial quality. The collaboration will provide critical insight into the quality of clinical trials, key drivers of that quality, and methods to improve clinical research.
CRO Analytics will develop a statistically validated data collection instrument to be used with the Performer™ platform, and work with ACRP to collect assessments from investigator site personnel. That data will be analyzed using the cloud-based SaaS software application through a series of algorithms and generate benchmarking, key driver analytics, and predictive analytics.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
